<DOC>
	<DOCNO>NCT01074060</DOCNO>
	<brief_summary>RATIONALE : There different method stem cell mobilization , use colony-stimulating factor alone follow chemotherapy prim . More recently , combination plerixafor colony-stimulating factor show enhance stem cell mobilization . This study ass whether combination plerixafor Granulocyte Colony-Stimulating Factor ( G-CSF ) effective follow chemotherapy mobilization cyclophosphamide . PURPOSE : To assess safety , tolerability , best dose intravenous plerixafor follow cyclophosphamide priming .</brief_summary>
	<brief_title>Plerixafor Filgrastim Following Cyclophosphamide Stem Cell Mobilization Patients With Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety tolerability intravenous ( IV ) PLERIXAFOR give combination cyclophosphamide G-CSF mobilization regimen patient Multiple Myeloma . SECONDARY OBJECTIVES : I . To determine intravenous PLERIXAFOR , give cyclophosphamide G-CSF mobilizing regimen , allow collection great equal 5 x 10^6 CD34+ cells/kg 2 less apheresis day . II . To review time intravenous plerixafor administration prior apheresis describe experience . OUTLINE : MOBILIZATION : Patients receive cyclophosphamide intravenously ( IV ) . Patients also receive filgrastim subcutaneously ( SC ) daily begin approximately 24 hour later . TREATMENT/APHERESIS : Beginning 10 day cyclophosphamide , patient receive plerixafor IV 30 minute follow filgrastim SC day apheresis . Following collection adequate number stem cell , patient undergo high-dose chemotherapy autologous stem cell rescue . Patients follow post-autologous stem cell transplant engraftment . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Criteria Inclusion exclusion criterion must reevaluate prior dose PLERIXAFOR ; patient meet criterion ( exclude hepatic hematologic criterion ) patient eligible continue unless Genzyme grant waiver Inclusion Eligible undergo autologous transplantation Diagnosed multiple myeloma ( MM ) ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 The patient recover acute toxic effect prior chemotherapy White Blood Count ( WBC ) &gt; 2.5 x 10^9/L Absolute neutrophil count &gt; 1.5 x 10^9/L Platelet count &gt; 100 x 10^9/L Serum creatinine &lt; = 2.5 mg/dl Creatinine clearance &gt; = 50 ml/min ( measure calculate ) Serum glutamic oxaloacetic transaminase ( SGOT ) &lt; 2 x ULN ( Upper Limit Normal ) Serum glutamic pyruvic transaminase ( SGPT ) &lt; 2 x ULN Total bilirubin &lt; 2 x ULN Left ventricle ejection fraction &gt; 45 % [ normal ECHO ( Echocardiogram ) MUGA ( MUltiple Gated Acquisition ) scan ] FEV1 ( forced expiratory volume 1 second ) &gt; 60 % predict DLCO ( Carbon Monoxide Diffusing Capacity ) &gt; 55 % predict No active infection hepatitis B C Negative HIV Signed inform consent ( may obtain anytime prior admission cytoxan ) Women child bear potential agree use approve form contraception Exclusion A comorbid condition , view investigator , render patient high risk treatment complication A residual acute medical condition result prior chemotherapy Brain metastases carcinomatous meningitis Acute infection Fever ( temp &gt; 38 degree C/100.4 degree F ) Positive pregnancy test female patient Lactating female Patients childbearing potential unwilling implement adequate birth control Prior treatment Plerixafor Prior stem cell transplant , either autologous allogeneic Prior cyclophosphamide prim Heart rate &lt; 50 screen Abnormal ECG ( electrocardiogram ) clinically significant rhythm disturbance conduction abnormality opinion investigator warrant exclusion subject trial Patients congestive heart failure screen History atrial fibrillation Patients currently medication control cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>